Core Viewpoint - LIXTE Biotechnology Holdings, Inc. has appointed Sidney Braun as the CEO of its subsidiary Liora Technologies Europe Ltd., aiming to advance cancer treatment technologies, particularly the LiGHT System for proton therapy [1][4]. Company Overview - LIXTE is a clinical-stage pharmaceutical and med-tech company focused on developing and commercializing cancer therapies, with its lead compound LB-100 showing promise in enhancing chemotherapy and immunotherapy outcomes [5]. - The company is pioneering a new treatment paradigm in cancer biology known as activation lethality, supported by a comprehensive patent portfolio [5]. Leadership Appointment - Sidney Braun brings over 20 years of operational and strategic experience in the healthcare industry, having played a significant role in the creation of Liora and the acquisition of its assets by LIXTE [2][3]. - Braun's commitment to advancing the radiotherapy segment aims to achieve positive patient outcomes and long-term shareholder value for LIXTE [4]. Technology Focus - Liora is developing electronically controlled proton therapy systems, with the LiGHT System believed to offer significant advantages over existing technologies for tumor treatment [6].

Company Overview - LIXTE Biotechnology Holdings Inc. is a clinical-stage pharmaceutical company focused on developing and commercializing cancer therapies, particularly through its lead compound LB-100, which is a first-in-class PP2A inhibitor [9][10] - The company is pioneering a new treatment paradigm in cancer biology known as activation lethality, supported by a comprehensive patent portfolio [10] - LIXTE is also developing electronically controlled proton therapy systems through its subsidiary, Liora Technologies Europe Ltd., with its flagship technology, the LiGHT System, believed to offer significant advantages in tumor treatment [11] Event Details - The inaugural Good Health: Mind, Body & Soul Summit, sponsored by LIXTE, will take place on February 19, 2026, at Morehouse College in Atlanta, focusing on health equity for Black men and families [2][3] - The event is inspired by the music and legacy of De La Soul, aiming to connect health, culture, and science to promote wellness [4][5] - The Summit will feature discussions on various health topics, including cancer, heart disease, mental health, and intergenerational wellness, bringing together health experts, artists, and community leaders [5]

Core Viewpoint - LIXTE Biotechnology Holdings, Inc. is advancing its first-in-class PP2A inhibitor, LB-100, and will participate in the DealFlow Discovery Conference to engage with investors [1][2]. Company Overview - LIXTE is a clinical-stage pharmaceutical company focused on developing and commercializing cancer therapies, particularly targeting new cancer drug development [2]. - The lead compound, LB-100, has shown to be well-tolerated in cancer patients and has the potential to enhance chemotherapies and immunotherapies [2][3]. Product Development - LB-100 is part of a new treatment paradigm in cancer biology known as activation lethality, with ongoing proof-of-concept clinical trials for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer, and Advanced Soft Tissue Sarcoma [3]. - LIXTE has a comprehensive patent portfolio covering its innovative approach to cancer treatment [3]. Subsidiary Operations - Through its subsidiary, Liora Technologies Europe Ltd., LIXTE is developing electronically controlled proton therapy systems, specifically the LiGHT System, which is expected to offer significant advantages over existing proton therapy technologies [4].

Core Insights - LIXTE Biotechnology Holdings, Inc. has acquired Liora Technologies Europe Ltd., marking its entry into the radiotherapy segment of cancer care [1][3] - The acquisition includes Liora's LiGHT System, which offers significant advantages in proton therapy for treating tumors [2][3] - The LiGHT System is expected to set a new standard in cancer treatment, providing high-precision therapy that is scalable and clinically versatile [3] Company Overview - LIXTE is a clinical-stage pharmaceutical company focused on developing and commercializing cancer therapies, with a lead compound, LB-100, that has shown promise in clinical trials [4][5] - The company aims to enhance existing cancer treatments through its innovative approach in cancer biology, specifically in activation lethality [5] Technology and Development - The LiGHT System, installed at STFC's Daresbury Laboratory, will serve as a center of excellence for proton therapy treatment [2] - The technology is designed to reduce installation costs and treatment sessions while increasing patient capacity at treatment centers [3]